Schizopherenia. Schizophrenia
Conditions
Interventions
Intervention 1: Olanzapine 10 mg/da. Intervention 2: Haloperidole 10 mg/day.
Treatment - Drugs
Olanzapine 10 mg/da
Haloperidole 10 mg/day
Sponsors
Deputy of Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 58 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: the criteria of DSM-IV for schizopherenia; neuroleptic drug-naive or drug-free for at least 4 weeks; age range from 18-58 years; filling consent form; no drug tranqulization for at least five half life of the drug; no psychoactive drug therapy for at least 5 half life of the drug. Exclusion criteria: Accompanied disorders of axis 1 or 2 based on DSM-IV; evidence of neurological disease; History of any drug abuse; elevating hepatic enzymes; pregnancy; thyroid dysfunction; consumption of drugs interferring with HT25 or D2 receptors.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alteration in cerebral perfusion. Timepoint: one month after using the drug. Method of measurement: cerebral perfusion scan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in severity of clinical symptoms. Timepoint: one month after onset of the treatment. Method of measurement: PANSS and CGI tests for clinical symptom score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Babak Fallahi
Research Institute for Nuclear Medicine, Tehran University of Medical Sciences
Outcome results
None listed